Strategic Focus Genprex is a clinical-stage biotech prioritizing gene therapy for cancer and diabetes, presenting joint opportunities across oncology and metabolic disease spaces for collaboration, licensing, or co-development with pharma and research institutions.

ONCOPREX Platform The proprietary non-viral ONCOPREX Nanoparticle Delivery System offers a systemic, intravenous gene delivery approach for tumor suppression pathways, signaling potential alignment with partners seeking novel delivery platforms and accelerated clinical programs.

Lead Programs REQORSA in NSCLC and SCLC with FDA Fast Track designations highlights a near-term value proposition for partnerships in lung cancer indications, companion diagnostics, and potential expansion into additional thoracic malignancies.

Collaborative Momentum Recent and ongoing collaborations, including with ALK Positive and participation in major conferences (BIO Europe Spring, AACR, ASGCT, ADA Scientific Sessions), indicate a readiness for co-development, funding conversations, and strategic alliances.

Financial and Growth Signals Reported revenue range and active fundraising activity, coupled with a lean team size, point to scalable partnership opportunities, sponsored research deals, and milestone-driven collaborations to accelerate clinical milestones.